- Assembly Biosciences Inc Extraordinary Shareholders Meeting TranscriptJan 31, 2024
- Assembly Biosciences Inc Partnership with Gilead Sciences Inc to Develop Next-Generation Antiviral Therapeutics Call TranscriptOct 17, 2023
- Assembly Biosciences Inc at Jefferies Healthcare Conference TranscriptJun 07, 2023
- Assembly Biosciences Inc Annual Shareholders Meeting TranscriptMay 25, 2023
- Assembly Biosciences Inc HSV-2 and Transplant-Associated Herpesviruses Research - Corporate Call TranscriptAug 31, 2022
- Assembly Biosciences Inc IFNAR (Interferon-a Receptor Agonist) Research - Corporate Call TranscriptJul 26, 2022
- Assembly Biosciences Inc HBV/HDV Entry Inhibitor Research - Corporate Call TranscriptMar 31, 2022
- Assembly Biosciences Inc Annual Shareholders Meeting TranscriptMay 20, 2021
- Assembly Biosciences Inc Earnings Call TranscriptFeb 25, 2021$66.36 (-1.95%)Earnings
- Assembly Biosciences, Inc. - Special Call TranscriptNov 05, 2020
- Assembly Biosciences, Inc. - Special Call TranscriptJul 20, 2020
- Assembly Biosciences Inc Annual Shareholders Meeting TranscriptJun 11, 2020
- Assembly Biosciences Inc to Discuss HBV Portfolio Progress Call TranscriptMay 07, 2020
- Assembly Biosciences, Inc. - Special Call TranscriptNov 11, 2019
- Assembly Biosciences, Inc Data Highlighting Next-Generation HBV Core Protein Inhibitors at EASL 2019 Call TranscriptApr 15, 2019
Assembly Biosciences, Inc. - Special Call Transcript
Good afternoon, and welcome to Assembly Bio's Phase II Expansion Study Update Webcast and Conference Call. (Operator Instructions) As a reminder, this conference call is being recorded.
I would now like to hand the call over to Lauren Glaser, Senior Vice President of Investor Relations and Corporate Affairs for Assembly Bio. Please go ahead.
Good afternoon, and thank you for joining us as we discuss interim results from Study 211, our Phase II extension study, monitoring patients with chronic hepatitis B virus for sustained virologic response or SVR, following discontinuation of treatment with vebicorvir and a nucleoside analogue.
This afternoon, we issued a press release providing an update on this ongoing study as well as a second press release reporting our financial results for the third quarter ended September 30, 2020. These press releases are available in the News and Events section of our corporate website at
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |
![](https://static.gurufocus.com/material/money-back-guarantee.png)
![](https://static.gurufocus.com/trust_rating.png)
![](https://static.gurufocus.com/trust.png)